https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-29 / Vaccine 2010 Nov;28(49):7764-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-29 / Vaccine 2010 Nov;28(49):7764-732010-09-29 00:00:002019-02-15 08:40:12Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-28 / Vaccine 2010 Nov;28(49):7787-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-28 / Vaccine 2010 Nov;28(49):7787-962010-09-28 00:00:002019-02-15 08:46:04Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-27 / J Transl Med 2010 Sep;8:89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-27 / J Transl Med 2010 Sep;8:892010-09-27 00:00:002019-02-15 08:49:23Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Int J Hyperthermia 2011;27(2):180-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Int J Hyperthermia 2011;27(2):180-62010-09-21 00:00:002019-02-15 09:17:26Intracavity hyperthermia in nasopharyngeal cancer: a phase III clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-92010-09-21 00:00:002010-09-21 00:00:00Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Int J Hyperthermia 2010;26(8):748-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Int J Hyperthermia 2010;26(8):748-642010-09-21 00:00:002019-02-15 10:00:35Measurement and mathematical modeling of thermally induced injury and heat shock protein expression kinetics in normal and cancerous prostate cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-07 / Cancer Res. 2010 Sep;70(18):7093-101
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-07 / Cancer Res. 2010 Sep;70(18):7093-1012010-09-07 00:00:002019-02-15 08:40:15IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-01 / Dan Med Bull 2010 Sep;57(9):B4171
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-01 / Dan Med Bull 2010 Sep;57(9):B41712010-09-01 00:00:002019-02-15 08:46:06Dendritic cell vaccination of patients with metastatic colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-01 / PLoS ONE 2010 Sep;5(9)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-01 / PLoS ONE 2010 Sep;5(9)2010-09-01 00:00:002019-02-15 08:52:57Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-01 / Anticancer Res 2010 Sep;30(9):3709-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-01 / Anticancer Res 2010 Sep;30(9):3709-142010-09-01 00:00:002024-03-18 10:58:36Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
